Health IT, Hospitals, Pharma, Startups

Cloud-based genome sequencing exchange could make personalized medicine easier for physicians

A genome sequencing platform to help physicians screen patients for the most appropriate drugs for […]

A genome sequencing platform to help physicians screen patients for the most appropriate drugs for their conditions such as for cancer treatments is one component of a new company that’s a spinout from a collaboration between Philadelphia-area Coriell Institute for Medical Research and its technology partner IBM.

Coriell Institute CEO Michael Christman and Scott Megill, Coriell’s chief information officer, who is leading the spinout, told MedCity News in a phone interview how the startup will work and explained its timeline.

Coriell Life Sciences in Camden, New Jersey,will be at the center of a genome ecosystem transmitting queries from physicians to genomic-sequencing interpreters. It will also provide cloud-based storage for each patient’s genomic sequence. It sees itself as something of an Amazon.com for genomic sequencing. It does not own the content, but through the ecosystem it is setting up, it is facilitating the interaction between physicians, researchers and the interpreters of that data. The company is making it easier to order, store and interpret genome sequence data for physicians.

Here’s how it works: A physician would order a test that requires genomic sequencing the same way he or she would order a diagnostic test. Coriell sends the sequencing order to a network of third-party interpreters it is in the process of assembling. The results will be transmitted to the patient’s medical records and the genome would be stored in its cloud-based vault. Physicians could use it to order follow-up tests or researchers could utilize the de-identified data.

Megill said he expects Coriell Life Sciences’ genome vault will be ready by early summer and its genomic exchange product is expected to be ready sometime this fall.

Christman said the startup’s programs would provide a huge economic benefit by helping the right patients get the right care at the right time. “We are at a special time [for genomic sequencing] where doctors want to use this tool.” For example, it would be able to identify patients who won’t respond well to Plavix — an anticlotting drug that’s ineffective for about 25 percent of the patients for whom it is prescribed. Instead, they could be prescribed U.S. Food and Drug Administration-approved alternative drugs and save a lot of money. “That’s just the tip of the iceberg,” Christman said. He also pointed out that genomic sequencing is increasingly being done in utero through the mother’s blood and negates a potentially more risky approach using amniocentesis.

IBM has been helping to build the technology platform for the spinout that will transmit the information gathered from the genomic sequencing data back to the patient’s medical records. It will also provide a secure way to store the cloud-based data.

The partnership with IBM dates back to 2011, when the company provided monitoring software to instantly alert Coriell researchers before any mechanical failure occurs and in turn, protect the integrity of its biological samples.

 [Photo from Flickr user andylepp]

Shares0
Shares0